Critical involvement of RQCD1 in the EGFR-Akt pathway in mammary carcinogenesis

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1085-1093

  Ajiro, Masahiko ^a   Nishidate, Toshihiko ^a   Katagiri, Toyomasa ^a,b   Nakamura, Yusuke ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Akt; Breast cancer; EGFR; RQCD1

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 10; PROTEIN GIGYF1; PROTEIN GIGYF2; PROTEIN KINASE B; PROTEIN RQCD1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOGENESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

EID: 77957875730     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000760     Document Type: Article

References (47)

1. Parkin DM, Bray F and Ferlay J: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Veronesi U, Boyle P, Goldhirsch A, Orecchia R and Viale G: Breast cancer. Lancet 365: 1727-1741, 2005.
3. Bange J, Zwick E and Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med 7: 548-552, 2001. (Pubitemid 32448320)
4. Nishidate T, Katagiri T, Lin ML, et al: Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 25: 797-819, 2004.
5. Saito-Hisaminato A, Katagiri T, Kakiuchi S, Nakamura T, Tsunoda T and Nakamura Y: Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 9: 35-45, 2002. (Pubitemid 36307043)
6. Park JH, Lin ML, Nishidate T, Nakamura Y and Katagiri T: PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 66: 9186-9195, 2006. (Pubitemid 44521139)
7. Lin ML, Park JH, Nishidate T, Nakamura Y and Katagiri T: Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res 9: R17, 2007. (Pubitemid 350215144)
8. Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y and Katagiri T: Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci 98: 174-181, 2007. (Pubitemid 44941869)
9. Shimo A, Tanikawa C, Nishidate T, et al: Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci 99: 62-70, 2008.
10. Ueki T, Nishidate T, Park JH, et al: Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene 27: 5672-5683, 2008.
11. Lin ML, Fukukawa C, Park JH, et al: Involvement of overexpression of G-patch domain containing 2 in breast carcinogenesis. Cancer Sci 100: 1443-1450, 2009.
12. Kim JW, Akiyama M, Park JH, et al: Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci 100: 1468-1478, 2009.
13. Ajiro M, Katagiri T, Ueda K, et al: Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol 35: 673-681, 2009.
14. Ueki T, Park JH, Nishidate T, Kijima K, Hirata K, Nakamura Y and Katagiri T: Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res 69: 8752-8760, 2009.
15. Park JH, Nishidate T, Nakamura Y and Katagiri T: Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci 101: 403-411, 2010.
16. Park JH, Nishidate T, Kijima K, et al: Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res 70: 2759-2769, 2010.
17. Okazaki N, Okazaki K, Watanabe Y, Kato-Hayashi M, Yamamoto M and Okayama H: Novel factor highly conserved among eukaryotes controls sexual development in fission yeast. Mol Cell Biol 18: 887-895, 1998. (Pubitemid 28063422)
18. Gregory RC, Lord KA, Panek LB, Gaines P, Dillon SB and Wojchowski DM: Subtraction cloning and initial characterization of novel Epo-immediate response genes. Cytokine 12: 845-857, 2000. (Pubitemid 30479465)
19. Hiroi N, Ito T, Yamamoto H, Ochiya T, Jinno S and Okayama H: Mammalian Rcd1 is a novel transcriptional cofactor that mediated retinoic acid-induced cell differentiation. EMBO J 21: 5235-5244, 2002.
20. Haas M, Siegert M, Shurmann A, Sodeik B and Wolfes H: c-Myb protein interacts with Rcd-1, a component of the CCR4 transcription mediator complex. Biochemistry 43: 8152-8159, 2004. (Pubitemid 38808270)
21. Garapaty S, Mahajan MA and Samuels HH: Components of the CCR4-NOT complex function as nuclear hormone receptor coactivators via association with the NRC-interacting factor NIF-1. J Biol Chem 283: 6806-6816, 2008.
22. Giovannone B, Lee E, Laviola L, Giorgino F, Cleveland KA and Smith RJ: Two novel proteins that are linked to insulin-like growth factor (IGF-l) receptors by the Grb10 adapter and modulate IGF-l signaling. J Biol Chem 34: 31564-31573, 2003. (Pubitemid 37048334)
23. Ooi J, Yajnik V, Immanuel D, Gordon M, Moskow JJ, Buchberg AM and Margolis B: The cloning of Grb10 reveals a new family of SH2 domain proteins. Oncogene 10: 1621-1630, 1995.
24. Stein E, Cerretti DP and Daniel TO: Ligand activation of ELK receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vescular endothelial cells. J Biol Chem 271: 23588-23593, 1996. (Pubitemid 26314813)
25. He Weimin, Rose DW, Olefsky JM and Gustafson TA: Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the Pleckstrin homology and SH2 domains. J Biol Chem 273: 6860-6867, 1998.
26. Wang J, Dai H, Yousaf N, et al: Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis. Mol Cell Biol 19: 6217-6228, 1999.
27. Jahn T, Seipel P, Urschel S, Peschel C and Duyster J: Role for the adaptor protein Grb10 in the activation of Akt. Mol Cell Biol 22: 979-991, 2002. (Pubitemid 34094836)
28. Nantel A, Huber M and Thomas DY: Localization of endogenous Grb10 to the mitochondria and its interaction with the mitochondrial-associated Raf1 pool. J Biol Chem 274: 35719-35724, 1999. (Pubitemid 129512873)
29. Deng Y, Bhattacharya S, Swamy OR, Tandon R, Wang Y, Janda R and Riedel H: Growth factor receptor-binding protein 10 (Grb10) as a partner of phosphatidylinositol 3-kinase in metabolic insulin action. J Biol Chem 278: 39311-39322, 2003. (Pubitemid 37248486)
30. Deng Y, Zhang M and Riedel H: Mitogenic roles of Gab1 and Grb10 as direct cellular partners in the regulation of MAP kinase signaling. J Cell Biochem 105: 1172-1182, 2008.
31. Abramoff MD, Magelhaes PJ and Ram SJ: Image processing with Image J. Biophotonics Int 11: 36-42, 2004.
32. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P and Hemmings BA: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551, 1996. (Pubitemid 26413787)
33. Yang J, Cron P, Thompson V, Good VM, Hess D, Hemmings BA and Barford D: Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 9: 1227-1240, 2002. (Pubitemid 34722302)
34. Scheid MP, Marignani PA and Woodgett JR: Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 22: 6247-6260, 2002.
35. Rojas M, Yao SY and Lin YZ: Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 271: 27456-27461, 1996. (Pubitemid 26367305)
36. Aziz SA, Pervez S, Khan S, Kayani N and Rahbar MH: Epidermal growth factor receptor (EGFR) as a prognostic marker: an immunohistochemical study on 315 consecutive breast carcinoma patients. J Pak Med Assoc 52: 104-110, 2002.
37. Buchholz TA, Tu X, Ang KK, et al: Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 104: 676-681, 2005.
38. DiGiovanna MP, Stern DF, Edgerton SM, et al: Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23: 1152-1160, 2005. (Pubitemid 46202271)
39. Tzaida O, Gogas H, Dafni U, et al: Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Oncology 72: 388-396, 2007.
40. Nieto Y, Nawaz F, Jones RB, et al: Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 25: 4405-4413, 2007. (Pubitemid 350013846)
41. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
42. Tan AR, Yang X, Hewitt SM, et al: Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22: 3081-3090, 2004.
43. Baselga J, Albanell J, Ruiz A, et al: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23: 5323-5333, 2005.
44. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743, 2006.
45. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28: 1301-1307, 2010.
46. Perez-Soler R and Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 23: 5235-5246, 2005.
47. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6: 803-812, 2006.